Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist. It is an investigational analgesic that may be a potential treatment for pain and/or inflammation.

Phase I trials have been completed in healthy Japanese and Caucasian volunteers.

Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.

When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days. It has a relatively long half-life between 68 and 101 hours in Japanese subjects and between 82 and 130 hours in Caucasian subjects.

Mavatrep is largely eliminated non-renally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.